Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

UPDATE - Summit Corp antibiotic could be fast-tracked under American initiative

Summit Corp’s drug candidate for C. difficile infection has been accepted to a US initiative designed to speed up the development of new antibiotics. 

---ADDS BROKER COMMENT AND SHARE PRICE---

Summit Corp’s (LON:SUMM) drug candidate for C. difficile infection has been accepted to a US initiative designed to speed up the development of new antibiotics.

The AIM-listed group’s SMT19969 has been designated by the Food & Drug Administration as a qualified infectious disease product under the Generating Antibiotics Incentives Now Act.

Practically, this means the treatment is eligible for priority review and fast track status.

And, if SMT19969 receives marketing approval from the FDA, it could receive a five-year extension of market exclusivity.  

Chief executive Edwards told investors: "This status recognises the serious healthcare threat posed by pathogens such as C. difficile and it will confer a number of advantages that will accelerate the development of this promising and differentiated antibiotic with the potential to treat initial CDI and reduce the high rates of disease recurrence, the major clinical issue."

SMT 19969 is currently undergoing phase II clinical trials with results of the study due in the first half of next year. 

C. difficile infection is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. 

Recurrent disease represents a key clinical issue with up to 30% of patients at risk of recurrent disease after the initial episode – and one it is hopes to tap into with 19969.

“This morning’s announcement is very positive particularly as QIDP status could extend the exclusivity period post launch of SMT19969,” said City broker N+1 Singer. 

The group, which is valued at £56mln, is developing two key drugs – the antibiotic and another that it is hope will provide hope to the fatal muscle wasting disease, Duchenne Muscular Dystrophy.

At 1.40pm, the shares were changing hands for 137p each, down 2p.


View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use